Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Damage Response (DDR) Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAD51D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAD51D Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW. |
View RAD51D Products |
| Gene Delivery | RAD51D Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View RAD51D Products |
| Benchmark Ab | Anti-RAD51D Recombinant Antibody Recombinant positive control for assay validation. |
View RAD51D Products |
| Validator | RAD51D siRNA Set For knockdown verification and target specificity assays. |
View RAD51D Products |
| Related Target A | RAD51C Synergistic complex partner in homologous recombination repair (BCDX2 complex). |
View RAD51C Products |
| Related Target B | PARP1 Synthetic lethality partner; key marker for sensitivity and resistance bypass. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) disruption screening | High-purity RAD51D and RAD51C recombinant proteins strictly verified by mass spectrometry for TR-FRET/AlphaLISA assays. |
| Selectivity screening against RAD51 family members | Homolog panel proteins (RAD51, RAD51B, RAD51C, XRCC2) available with high purity and sequence verification. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks and target validation |
Live RAD51D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAD51D therapeutics is intensifying, with major players shifting focus from traditional PARP inhibitors to targeting homologous recombination repair (HRR) components directly. As first-generation therapies reach the clinic, the next wave of R&D is targeting RAD51D protein-protein interactions (PPI) and ATPase activity to overcome acquired PARP inhibitor resistance. RAD51D mutations serve as critical biomarkers for synthetic lethality, making the target highly attractive in breast, ovarian, and prostate cancer indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Artios Pharma, IDEAYA Biosciences | Ovarian Cancer, Breast Cancer, Prostate Cancer | Selectivity Assay (Need Mutant vs WT Proteins and family homologs) |
| PROTAC / Degraders | Arvinas, Kymera Therapeutics | DDR-deficient Solid Tumors | Target Degradation Assay (Need high-purity RAD51D and stable cell line constructs) |
| Combination Therapies | AstraZeneca, GSK | PARPi-Resistant Tumors | Synergy Validation (Need PARP1 and RAD51D co-expression/knockdown panels) |